Mangoceuticals approved terms for preferred shares that could bring cash, but they would receive 8% dividends and earlier claims if the company is liquidated. The terms are not effective, and the company may abandon them, so no sale or new share claims have taken effect.
If completed, a sale could bring Mangoceuticals cash. The preferred shares would also receive dividends before common shares and rank ahead of them if the company is liquidated. The terms are not effective, and the company may drop the plan, so no financing or new share claims are in place yet.
Follow Mangoceuticals, Inc. (MGRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MGRX